Company Intelligence

Multiply Labs

The traditional manufacturing process for individualized drugs is extremely slow and expensive, because it is based on manual labor. At Multiply Labs, we believe that robotics is the only way to truly scale the production of…

In this profile

Quick Facts

  • Founded 2016
  • Headquarters San Francisco, United States
  • Country United States
  • Industry AI in Manufacturing
  • Company Type Growth
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

The traditional manufacturing process for individualized drugs is extremely slow and expensive, because it is based on manual labor. At Multiply Labs, we believe that robotics is the only way to truly scale the production of individualized drugs - finally providing these life-saving therapies to the millions of patients who need them. We develop cloud-controlled modular robotic systems that manufacture individualized drugs, and we deploy these systems in the facilities of our pharma customers. This is pharma robotics as a service: we sell the robotic production capacity that our customers need to scale their next-gen individualized drugs.

Why It Matters

Robotic production capacity for the pharma manufacturing industry

Recent Developments

  1. 2016 Company founded

    Multiply Labs was founded in 2016 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

The traditional manufacturing process for individualized drugs is extremely slow and expensive, because it is based on manual labor. At Multiply Labs, we believe that robotics is the only way to truly scale the production of individualized drugs – finally providing these life-saving therapies to the millions of patients who need them. We develop cloud-controlled modular robotic systems that manufacture individualized drugs, and we deploy these systems in the facilities of our pharma customers. This is pharma robotics as a service: we sell the robotic production capacity that our customers need to scale their next-gen individualized drugs.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe